DUBLIN–(BUSINESS WIRE)–The “Exocrine Pancreatic Insufficiency (EPI) – Market Insights, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This ‘Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast- 2030’ report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Exocrine Pancreatic Insufficiency (EPI) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Exocrine Pancreatic Insufficiency (EPI) Drug Chapters
The drug chapter segment of the Exocrine Pancreatic Insufficiency (EPI) report encloses the detailed analysis of Exocrine Pancreatic Insufficiency (EPI) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Exocrine Pancreatic Insufficiency (EPI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Exocrine Pancreatic Insufficiency (EPI) Market Outlook
The treatment landscape of EPI majorly includes pancreatic enzyme replacement therapy (PERT), lifestyle modifications (e.g., avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet) and vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K).
Pancreatic enzyme replacement therapy (PERT) is the first line therapeutic mainstay that is prescribed in patients. The pancreatic enzyme products (PEPs) used for PERT are extracts of porcine pancreas that contain all three pancreatic enzymes (i.e., amylase, protease, and lipase) in varying proportions. However, it is lipase that plays the paramount role in therapy.
Pharmacological therapies are the mainstay treatment option followed by the patients with EPI. The market of EPI includes use of the drugs either as monotherapy and are not interchangeable. There are several approved drugs in the market of different classes.
The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Exocrine Pancreatic Insufficiency (EPI) 7MM market is expected to change in the study period 2017-2030.
Key Topics Covered:
1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance
4.1 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017
4.2 Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030
5 Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)
5.1 Introduction
5.2 Biology and pathology of Exocrine Pancreatic Insufficiency
5.3 Pathophysiology of EPI
5.4 Causes and Risk Factors of EPI
5.4.1 EPI caused by pancreatic disorders
5.4.2 EPI caused by extrapancreatic disorders
5.5 Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis
5.5.1 Disorders of Carbohydrate Metabolism
5.5.1 Disorders of Lipid Metabolism
5.6 Diagnosis
5.6.1 Fecal elastase-1 test (FE-1)
5.6.2 Serum trypsinogen
5.6.3 Fecal chymotrypsin
5.6.4 Breath tests
5.6.5 Coefficient of fat absorption (CFA)
5.6.6 Preoperative Evaluation
5.6.7 Direct pancreatic function test
5.6.8 Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)
5.6.9 Differential Diagnosis of exocrine pancreatic insufficiency
6 Recognized Establishments
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7 Major Markets
7.2.1 Prevalence of Causative Indications of EPI in the 7MM
7.2.2 Prevalence of Exocrine Pancreatic Insufficiency in the 7MM
8 Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)
8.1 Assumption and Rationale
8.1 United States
8.1.1 Prevalence of Causative Indications of EPI in the United States
8.1.2 Prevalence of Exocrine Pancreatic Insufficiency in the United States
8.2 EU5 Countries
8.2.1 Assumption and Rationale
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 The United Kingdom
8.8 Japan
9 Treatment
9.1.1 Dietary management and lifestyle changes
9.1.2 Pancreatic enzyme replacement therapy (PERT)
9.1.3 Patient Journey of EPI with Gastrointestinal Disorders in Diabetes
10 Unmet Needs
11 Marketed Drugs
11.1 Key-cross Competition
11.2 Pertzye (pancrelipase): Digestive Care
11.3 Creon (pancrelipase)/Lipacreon: AbbVie
11.4 Zenpep (pancrelipase): Nestle
11.5 Pancreaze: Janssen Pharmaceuticals
11.6 Viokace (pancrelipase): Aptalis Pharma/Forest Laboratories
11.7 RELiZORB: Alcresta Therapeutics
11.8 Ultresa (pancrelipase): Aptalis Pharma/Forest Laboratories
12 Emerging Drugs
12.1 Omeprazole: Chiesi Farmaceutici
12.2 MS1819-SD: AzurRx BioPharma
13 Exocrine Pancreatic Insufficiency (EPI): 7 Major Market Analysis
13.1 Key Findings
13.1 Total Market Size of Exocrine Pancreatic Insufficiency (EPI) in the 7MM Countries
13.1.1 Market Size by Therapies
14 Conjoint Analysis
15 7MM Market Outlook
16 United States Market Size
16.1.1 Total Market size of Exocrine Pancreatic Insufficiency (EPI)
16.1.2 Market Size by Therapies
17 EU-5 Market Size
18 Access and Reimbursement Overview: Exocrine Pancreatic Insuffficiency (EPI)
19 Case Reports
19.1 A Case Report of exocrine pancreatic insufficiency in palliative care patient
19.2 Case Report of a Patient with Pancreatic Exocrine Insufficiency and Enteral Feeding
19.3 Case Report of a Pancreatic Exocrine Insufficiency Patient with Systemic Edema after Pancreaticoduodenectomy
20 Market Drivers
21 Market Barriers
For more information about this report visit https://www.researchandmarkets.com/r/6bxpgr
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900